By a News Reporter-Staff News Editor at Hematology Week -- Current study results on Stroke have been published. According to news reporting originating in Padua, Italy, by NewsRx journalists, research stated, "In this overview we address the three phase III studies that compared new oral anticoagulants (dabigatran, rivaroxaban and apixaban) with warfarin in the setting of stroke prevention in atrial fibrillation. Strengths and weaknesses of the studies were examined in detail through indirect comparison."
The news reporters obtained a quote from the research from the University of Padua, "We analyze and comment the inclusion and exclusion criteria, the characteristics of randomized patients, the primary efficacy and safety end points and side effects. All new oral anticoagulants resulted in being non-inferior to vitamin K antagonists in reducing stroke or systemic embolism in patients with atrial fibrillation. Dabigatran 150 mg and apixaban were superior to vitamin K antagonists. Importantly, new oral anticoagulants significantly reduced hemorrhagic stroke in all three studies. Major differences among new oral anticoagulants include the way they are eliminated and side effects. Both dabigatran and apixaban were tested in low-to moderate-risk patients (mean CHADS2 [Congestive heart failure, Hypertension, Age, Diabetes, Stroke] score=2.1-2.2) whereas rivaroxaban was tested in high-risk patients (mean CHADS2 score=3.48) and at variance with dabigatran and apixaban was administered once daily. Apixaban significantly reduced mortality from any cause."
According to the news reporters, the research concluded: "The choice of a new oral anticoagulant should take into account these and other differences between the new drugs."
For more information on this research see: Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of Thrombosis and Haemostasis, 2012;10(10):1979-87. (Wiley-Blackwell - www.wiley.com/; Journal of Thrombosis and Haemostasis - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1538-7836)
Our news correspondents report that additional information may be obtained by contacting V. Pengo, Dept. of Clinical Cardiology, Thrombosis Centre, University of Padua, Padua, Italy. Additional authors for this research include L. Crippa, A. Falanga, G. Finazzi, F. Marongiu, M. Moia, G. Palareti, D. Poli, S. Testa, E. Tiraferri, A. Tosetto, A. Tripodi, S. Siragusa and C. Manotti (see also Stroke).
Keywords for this news article include: Padua, Italy, Europe, Stroke.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.